Bottom line
A marketed growth-hormone-axis combination pairing a substance labeled “CJC-1295 (no DAC)” with GHRP-6, a first-generation hexapeptide ghrelin-receptor agonist. Acute human component studies report GH release from GHRP-6, while a feeding response has been demonstrated directly in rats. No combination-specific study was identified.
No established or recommended human dose.
Name and formulation variability
| Market observation (source/date) | Claimed components and amounts | Verification limits | |---|---|---|---| | Online-market listings observed in 2026 | No-DAC identity caveat: substance labeled “CJC-1295 (no DAC)” plus GHRP-6; variable amount | Seller-declared identity and amount are not independent verification; “no DAC” means Modified GRF 1-29 rather than the DAC conjugate studied as CJC-1295 |
Also known as: CJC-1295/GHRP-6, Mod GRF 1-29/GHRP-6. GHRP-6 was first synthesised in 1984 as an enkephalin analog without opioid activity.
Critical ambiguity: the clinical-study name CJC-1295 refers to the DAC conjugate designed for albumin binding. Online-market “CJC-1295 no DAC” usually refers to Modified GRF 1-29, a different substance. Evidence for CJC-1295 DAC cannot be transferred to Modified GRF 1-29 or this blend.
CJC-1295 with DAC has a separate study record but is a different identity from the marketed no-DAC label. GHRP-6 has separate small human endocrine studies. Only the no-DAC label and GHRP-6 are market-associated with the pair, and no combination evidence was identified.
Component evidence
| Component | Separate evidence | Combination evidence | Compatibility |
|---|---|---|---|
| CJC-1295 no DAC | Design: no controlled human study of the exact material identified. Endpoint type: receptor activity inferred from sequence and class. Limitation: DAC evidence concerns a different identity. | Shared gap: not identified | No published data |
| GHRP-6 | Design: small acute human endocrine studies. Endpoint type: GH and other pituitary-hormone responses, not therapeutic outcomes. Limitation: GHRP-6 alone or with GHRH is not this marketed pair. | Shared gap: not identified | Not identified |
GHRP-6's appetite effect is commonly presented as a differentiator from more selective secretagogues. Direct evidence identified here is Evidence from in vitro or animal studies with no adequate human efficacy evidence — the atlas Grade D lane. Источник определения: Evidence grading methodology · Глоссарий: an intracerebroventricular rat study reported increased feeding after GHRP-6. That animal observation does not establish a human appetite effect or the effect, safety, or value of this marketed combination.
A separate uncontrolled phase 1 report by Selman-Housein et al. enrolled 18 healthy adults aged 18–35 years, three at each of six single Administered into a vein. Источник определения: Neutral gloss; usage context: Routes, devices, and absorption primer · Глоссарий exposures from 1 to 400 mcg/kg. It recorded 23 adverse events in 12 participants and no serious adverse event. This small dose-escalation study did not test the blend.
Study detail
Ilson 1989 studied 17 healthy men during 30-minute IV infusions of 0.05–2.5 mcg/kg and included eight saline control infusions; GH increased with exposure and peaked at 45 minutes. Bowers 1990 studied 18 healthy men after IV boluses of 0.1, 0.3, or 1 mcg/kg, alone or with GHRH at 1 mcg/kg. GH responses were exposure-related, the two lower combined exposures were described as synergistic, and prolactin and cortisol rose about twofold only at the highest GHRP-6 exposure. A separate uncontrolled report enrolled 18 healthy adults across six single-exposure cohorts and did not test the blend. These descriptive records are not instructions.
Combination-specific studies
A targeted PubMed search through 2026-08-06 identified no published human or animal study testing CJC-1295 + GHRP-6 as a specific combination. Related GHRH-analog and GHRP-6 findings come from separate component literature.
Safety and interaction uncertainties
Appetite stimulation has direct Evidence from in vitro or animal studies with no adequate human efficacy evidence — the atlas Grade D lane. Источник определения: Evidence grading methodology · Глоссарий support but was not established in the cited human studies
Cortisol/prolactin elevation at the highest acute GHRP-6 exposure complicates endocrine readouts
No combination-specific safety data
Fixed-ratio blend prevents independent dose adjustment of either component
Regulatory and product-quality notes
Neither component FDA-approved
The cited human GHRP-6 studies were acute or single-exposure studies and do not establish therapeutic efficacy
The 2026 The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. Источник определения: WADA and sport regulation brief · Глоссарий List explicitly names CJC-1295 among GHRH analogues and GHRP-6 among GH-releasing peptides in section S2.2.4; both are prohibited at all times
An online “research use only” label is not authorization for human use
Evidence gaps
No combination study of any kind
No dose-ratio optimisation
No co-stability or co-Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. Источник определения: Lyophilization, formulation, and stability primer · Глоссарий characterisation
Long-term safety was not established in the cited individual-component studies or for the combination
Compare the identity boundary in CJC-1295 + Ipamorelin and the product-status boundary in CJC-1295 + GHRP-2. The WADA page addresses sport status separately.
Sources
Ilson BE, et al. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab. 1989;69(1):212-214. PMID 2543692. https://pubmed.ncbi.nlm.nih.gov/2543692/
Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. PMID 2108187. https://pubmed.ncbi.nlm.nih.gov/2108187/
Selman-Housein KH, et al. Clinical safety of GHRP-6 in healthy volunteers. Invest Medicoquir. 2014;6(1):81-91. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=50887
Lawrence CB, et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002;143(1):155-162. PMID 11751604. https://pubmed.ncbi.nlm.nih.gov/11751604/
PubChem. GHRP-6, CID 4345065. https://pubchem.ncbi.nlm.nih.gov/compound/4345065
World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf